IO120
/ IO Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 21, 2022
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
(clinicaltrials.gov)
- P2 | N=19 | Completed | Sponsor: Lars Møller Pedersen | Active, not recruiting ➔ Completed
IO biomarker • Trial completion • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • IGH
February 21, 2021
Peptide Vaccination With IO103 and IO120 in Patients With Chronic Lymphocytic Leukemia.
(clinicaltrials.gov)
- P2; N=20; Active, not recruiting; Sponsor: Lars Møller Pedersen; Trial completion date: Oct 2020 ➔ Mar 2021; Trial primary completion date: Oct 2020 ➔ Mar 2021
Clinical • IO biomarker • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • IGH
August 12, 2020
Peptide Vaccination With IO103 and IO120 in Patients With Chronic Lymphocytic Leukemia.
(clinicaltrials.gov)
- P2; N=20; Active, not recruiting; Sponsor: Lars Møller Pedersen; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • IO Biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • IGH
1 to 3
Of
3
Go to page
1